Latest Regulatory News

Arcadia Minerals (ASX: AM7) has denied possessing any undisclosed information following a sharp rise in its share price and volume. The company retracted parts of a recent market update related to its negotiations with Xinhai Mining Services and confirmed compliance with ASX disclosure rules.

NeuRizer Ltd advanced its urea project with Reliance Industries payments and environmental submissions, despite ongoing ASX trading suspension and overdue financial reports.

Arovella Therapeutics undergoes a major board overhaul and CEO resignation following a shareholder push, as the company embarks on a strategic review of its cell therapy platform.

AdAlta has secured A$2.5 million in a strategic placement to push its lead CAR-T therapy BZDS1901 through critical US FDA regulatory steps and establish Australian manufacturing, building on promising clinical responses in advanced mesothelioma.

Navigator Global Investments (ASX: NGI) is acquiring a US$195 million portfolio of Net Revenue Share interests from Stable Asset Management, broadening its alternative asset manager ecosystem and raising A$145 million via a fully underwritten entitlement offer.

Ballymore Resources is raising $3.24 million through a non-renounceable entitlement offer to fund drilling, geophysical surveys, and trial mining across key Queensland projects, including Dittmer and Ruddygore.

Botala Energy Ltd has denied holding undisclosed information following a sharp share price rise, linking the spike to a recent Serowe CBM Project announcement and confirming compliance with ASX disclosure rules.

Avira Resources has cleared all major regulatory and heritage hurdles to kick off a 4,500-metre RC drilling campaign at its high-grade Mt Cattlin Gold Project, aiming for a maiden resource estimate by year-end.

The Hydration Pharmaceuticals Company Limited (ASX: HPC) has had its trading suspension lifted as of 4 May 2026, following the lodgement of its delayed Annual Report revealing a $2.86 million net loss.

GR Production Services secures a five-year $57 million operations and maintenance contract at the Sturt Plateau Compression Facility in the Northern Territory's Beetaloo Basin, with potential extension for three more years.

PYC Therapeutics presented Phase 1/2 data at ARVO 2026 showing encouraging safety and efficacy signals for its RNA therapies targeting rare genetic eye diseases Retinitis Pigmentosa type 11 and Autosomal Dominant Optic Atrophy.

Imricor Medical Systems has secured A$60 million through a placement to fund its US commercial rollout, regulatory approvals, and clinical programs, boosting its cash reserves to nearly A$103 million.